FOP News

Next Step in Clementia's Clinical Program for FOP

Enrollment information and FAQs

The IFOPA is pleased to share the announcement and new FAQs from Clementia Pharmaceuticals regarding the palovarotene clinical trial.

Read more Share

Penn Animal Study Findings Announced

FOP Flare-Ups

The IFOPA is pleased to share the press release and editorial from the Perelman School of Medicine at the University of Pennsylvania about their Animal Study Findings on FOP Flare-Ups and Low Oxygen.

Read more Share

FOP study conducted by researchers at Penn Medicine and CHOP

Results Announced

The IFOPA is pleased to share these announcements from the Perelman School of Medicine/University of Pennsylvania Health System and Clementia Pharmaceuticals sharing results of a study conducted by researchers at Penn Medicine and Children’s Hospital of Philadelphia (CHOP) on the effects of palovarotene in an animal model of Fibrodysplasia Ossificans Progressiva (FOP). 

Read more Share

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter